Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_assertion type Assertion NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_head.
- NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_assertion wasGeneratedBy ECO_0000203 NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_provenance.
- NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_assertion wasDerivedFrom befree-20150227 NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_provenance.
- NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_assertion SIO_000772 15248218 NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_provenance.
- NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_assertion evidence source_evidence_literature NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_provenance.
- NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341581.RA7MDfDfCDVNRCgicC_mvGS6bPVwr8pD6R4GIGh6AB-Rk130_provenance.